anonymised participant-level data (Astellas)
90
Structured Review
Astellas
anonymised participant-level data
Anonymised Participant Level Data, supplied by Astellas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+data/anonymized+participant+level+data/pm39581908-203-6-13
Average 90 stars, based on 1 article reviews
Anonymised Participant Level Data, supplied by Astellas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+data/anonymized+participant+level+data/pm39581908-203-6-13
Average 90 stars, based on 1 article reviews
anonymised participant-level data - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Tacrolimus use and renal function in pregnancy with lupus nephritis: Analysis of post-marketing surveillance data in Japan. Article Snippet: Researchers may request access to anonymised Article Title: Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study Article Snippet: Researchers may request access to anonymised Article Title: Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study. Article Snippet: Researchers may request access to anonymised Article Title: Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. Article Snippet: MB, Article Title: Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease Article Snippet: Researchers may request access to anonymised Clinical Proteomics:Article Title: Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysis. Article Snippet: .. Details for how researchers may request access to anonymised Article Title: Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Article Snippet: Medical writing support was provided by Michael Parsons from Envision Pharma Ltd. (Horsham, UK) and was funded by the study sponsor. .. Data sharing statement: Details on how researchers may request access to anonymised |